Skyrizi (risankizumab) vs Yuflyma (adalimumab-aaty)

Skyrizi (risankizumab) and Yuflyma (adalimumab-aaty) are both used to treat inflammatory conditions such as plaque psoriasis, but they work in different ways. Skyrizi is an IL-23 inhibitor that targets a specific pathway in the immune system to reduce inflammation, and is typically administered once every three months after two starter doses. Yuflyma, a biosimilar to Humira, is a TNF inhibitor that is usually given every other week, and has a broader range of indications including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, in addition to plaque psoriasis. When deciding which medication is right for an individual, one should consider factors such as the specific condition being treated, the frequency of dosing, potential side effects, and how the medication's action aligns with their unique health profile, in consultation with a healthcare provider.

Difference between Skyrizi and Yuflyma

Metric	Skyrizi (risankizumab)	Yuflyma (adalimumab-aaty)
Generic name	Risankizumab	Adalimumab-aaty
Indications	Plaque psoriasis, psoriatic arthritis	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis
Mechanism of action	IL-23 inhibitor	TNF blocker
Brand names	Skyrizi	Yuflyma
Administrative route	Subcutaneous injection	Subcutaneous injection
Side effects	Upper respiratory infections, headache, fatigue, injection site reactions	Infections, injection site reactions, headache, rash, nausea
Contraindications	Known hypersensitivity to risankizumab or excipients	Known hypersensitivity to adalimumab or excipients, active tuberculosis, other severe infections
Drug class	Monoclonal antibody	Monoclonal antibody
Manufacturer	AbbVie	Celltrion Healthcare

Efficacy

Efficacy of Skyrizi (risankizumab) in Psoriatic Arthritis

Skyrizi (risankizumab) is a biologic medication approved for the treatment of moderate to severe plaque psoriasis. While it has shown efficacy in treating psoriasis, its use in psoriatic arthritis is still under investigation. Clinical trials are ongoing to evaluate the effectiveness of risankizumab in patients with psoriatic arthritis. Preliminary data suggests that risankizumab may help in reducing the signs and symptoms of psoriatic arthritis, improving physical function, and inhibiting the progression of structural damage as measured by radiographic findings. However, as of the knowledge cutoff date, Skyrizi has not received approval for the treatment of psoriatic arthritis, and more research is needed to fully understand its efficacy and safety profile for this condition.

Efficacy of Yuflyma (adalimumab-aaty) in Psoriatic Arthritis

Yuflyma (adalimumab-aaty) is a biosimilar to the reference product adalimumab, which is widely used in the treatment of several inflammatory conditions, including psoriatic arthritis. Adalimumab, a tumor necrosis factor (TNF) inhibitor, has been shown to be effective in reducing the clinical signs and symptoms of psoriatic arthritis, improving physical function, and slowing the progression of joint damage. As a biosimilar, Yuflyma is highly similar to the reference product and has no clinically meaningful differences in terms of safety, purity, and potency. It is expected to have similar efficacy to the reference product in the treatment of psoriatic arthritis, based on the totality of evidence required for biosimilar approval.

Clinical trials for the reference product have demonstrated significant improvements in joint symptoms, skin lesions, enthesitis, and dactylitis with adalimumab treatment. Patients with psoriatic arthritis treated with adalimumab also reported improvements in quality of life and functional ability. Given that Yuflyma has been approved as a biosimilar, it is anticipated to offer comparable therapeutic benefits for patients with psoriatic arthritis. However, healthcare providers should review the latest clinical data and guidelines when considering Yuflyma for the management of psoriatic arthritis.

In conclusion, while Skyrizi is still under investigation for its efficacy in psoriatic arthritis, Yuflyma, as a biosimilar to adalimumab, is expected to provide similar efficacy in the treatment of this condition. Patients and healthcare providers should discuss the most appropriate treatment options based on individual patient needs, the latest research findings, and clinical practice guidelines.

Regulatory Agency Approvals

Skyrizi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Yuflyma

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Skyrizi or Yuflyma today

If Skyrizi or Yuflyma are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Skyrizi

Buy Yuflyma

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: